Dana‑Farber/Harvard lung cancer program
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
['FUNDING_OTHER'] · DANA-FARBER CANCER INST · NIH-11190796
A Boston program that develops new treatments and tests for people with lung cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11190796 on ClinicalTrials.gov |
What this research studies
This program brings together researchers from Dana‑Farber, Mass General, Brigham and Women’s, Beth Israel Deaconess, and Boston Children’s to speed lab discoveries into patient care. It supports multiple linked projects and shared cores that study tumor biology, targetable mutations (like EGFR and ALK), the immune response, and new vaccine or drug approaches. The program funds clinical trials, collection of patient samples, and early translational work to move promising ideas toward people with lung cancer. It also supports new investigators so fresh therapies and tests can enter clinical testing more quickly.
Who could benefit from this research
Good fit: People with lung cancer—particularly those with advanced, recurrent, or molecularly defined tumors (for example EGFR‑ or ALK‑positive)—are the most likely candidates for trials and sample donation.
Not a fit: People without lung cancer or those already cured by standard treatment are unlikely to receive direct benefit from this program's clinical projects.
Why it matters
Potential benefit: If successful, the program could produce more effective targeted therapies, better biomarkers, and new clinical trials that improve outcomes and quality of life for people with lung cancer.
How similar studies have performed: Prior work from this SPORE helped discover EGFR mutations and led to development of EGFR and ALK targeted drugs, showing this translational approach has produced major clinical successes.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BARBIE, DAVID A — DANA-FARBER CANCER INST
- Study coordinator: BARBIE, DAVID A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center, Cancer Genes